



US008877938B2

(12) **United States Patent**
Feng et al.

(10) **Patent No.:** **US 8,877,938 B2**
(45) **Date of Patent:** **Nov. 4, 2014**

(54) **COMPOUNDS CONTAINING S-N-VALERYL-N-([2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL)-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPYONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS**

(75) Inventors: **Lili Feng**, Pine Brook, NJ (US); **Sven Erik Godtfredsen**, Chatham, NJ (US); **Bin Hu**, Green Brook, NJ (US); **Yugang Liu**, Bridgewater, NJ (US); **Piotr Karpinski**, Lincoln Park, NJ (US); **Paul Allen Sutton**, Parsippany, NJ (US); **Mahavir Prashad**, Montville, NJ (US); **Michael J. Girgis**, Montville, NJ (US); **Thomas J. Blacklock**, Clark, NJ (US)

(73) Assignee: **Novartis Pharmaceuticals Corporation**, East Hanover, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 200 days.

(21) Appl. No.: **11/722,360**

(22) PCT Filed: **Nov. 8, 2006**

(86) PCT No.: **PCT/US2006/043710**
§ 371 (c)(1),
(2), (4) Date: **Jan. 15, 2008**

(87) PCT Pub. No.: **WO2007/056546**
PCT Pub. Date: **May 18, 2007**

(65) **Prior Publication Data**
US 2009/0156585 A1 Jun. 18, 2009
Related U.S. Application Data

(60) Provisional application No. 60/735,093, filed on Nov. 9, 2005, provisional application No. 60/735,541, filed on Nov. 10, 2005, provisional application No. 60/789,332, filed on Apr. 4, 2006, provisional application No. 60/822,086, filed on Aug. 11, 2006.

(51) **Int. Cl.**
C07D 257/04 (2006.01)
C07C 233/47 (2006.01)
A61K 31/41 (2006.01)
A61K 31/4422 (2006.01)
A61K 31/5415 (2006.01)

(52) **U.S. Cl.**
CPC **C07D 257/04** (2013.01); **C07C 233/47** (2013.01); **A61K 2300/00** (2013.01); **A61K 31/4422** (2013.01); **A61K 31/5415** (2013.01); **A61K 31/41** (2013.01)
USPC **548/253**; 514/381

(58) **Field of Classification Search**
CPC C07D 257/04; C01C 233/47; A61K 2300/00; A61K 31/4422; A61K 31/5414
USPC 548/253; 514/381
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS

4,610,816 A 9/1986 Berger
4,722,810 A 2/1988 Delaney et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP 0 342 850 11/1989
EP 0 343 911 11/1989

(Continued)

OTHER PUBLICATIONS

Morissette et al.; "High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids"; 2004; Advanced Drug Delivery Reviews; 56: 275-300.*

(Continued)

Primary Examiner — Timothy Thomas

(74) *Attorney, Agent, or Firm* — Matthew Mulkeen

(57) **ABSTRACT**

A compound of an angiotensin receptor antagonist (ARB), a neutral endopeptidase inhibitor (NEPi) and one or more monovalent cations are useful for the treatment of hypertension and/or heart failure. ARB includes S—N-valeryl-N-([2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine in the anion form, NEPi includes (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form and cation includes monovalent cations such as Na⁺. The compound includes trisodium [3-((1S, 3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3'-methyl-2'-(pentanoyl{2"-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate] hemipentahydrate.

14 Claims, 1 Drawing Sheet

not used in the representative sample of MedChem 5/15/2014
Copyright © 2014 Novartis Pharmaceuticals Corporation, East Hanover, NJ 07930
All rights reserved. No part of this document may be reproduced without written permission from Novartis Pharmaceuticals Corporation.

